Published in Ann Rheum Dis on October 29, 2007
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther (2011) 1.17
Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J Gastroenterol (2011) 1.03
Infliximab: 12 years of experience. Arthritis Res Ther (2011) 0.99
Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis (2011) 0.99
A systematic MEDLINE analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int (2009) 0.98
Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis (2013) 0.91
What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med (2014) 0.83
[Recommendations for use of rituximab in patients with rheumatoid arthritis]. Z Rheumatol (2014) 0.82
Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol (2012) 0.82
Prevalence and characteristics of lung involvement on high resolution computed tomography in patients with ankylosing spondylitis: a systematic review. Pulm Med (2012) 0.82
Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis. Health Qual Life Outcomes (2014) 0.81
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis. Ther Clin Risk Manag (2015) 0.80
Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther (2012) 0.79
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. Z Rheumatol (2014) 0.77
Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study. Cost Eff Resour Alloc (2015) 0.77
Ankylosing spondylitis in Ireland: patient access and response to TNF-α blockers. Rheumatol Int (2011) 0.77
Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis. Rheumatol Int (2008) 0.77
Spondyloarthritides: evolving therapies. Arthritis Res Ther (2010) 0.77
The Bath metrology index as assessed by a trained and an untrained rater in patients with spondylarthropathy: a study of intra- and inter-rater agreements. Clin Rheumatol (2008) 0.77
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord (2015) 0.77
Impact of biological therapy on spondyloarthritis. Eur J Clin Pharmacol (2014) 0.76
Concurrent Intervention With Exercises and Stabilized Tumor Necrosis Factor Inhibitor Therapy Reduced the Disease Activity in Patients With Ankylosing Spondylitis: A Meta-Analysis. Medicine (Baltimore) (2015) 0.76
Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study. Arthritis Res Ther (2014) 0.76
Current issues in pediatric inflammatory bowel disease-associated arthropathies. World J Gastroenterol (2014) 0.75
Inter-rater reliability of clinical mobility measures in ankylosing spondylitis. BMC Musculoskelet Disord (2016) 0.75
Clinical and radiographic response to a local infliximab injection in a patient with chronic sacroiliitis. Nat Clin Pract Rheumatol (2009) 0.75
Management of ankylosing spondylitis with infliximab. Open Access Rheumatol (2009) 0.75
Clinical observations programme in SpA: disease parameters, treatment options and practical management issues. Rheumatol Int (2008) 0.75
The synovio-entheseal complex in enthesoarthritis. Clin Exp Med (2015) 0.75
[Ankylosing spondylitis. Target treatment criteria]. Z Rheumatol (2009) 0.75
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47
Active immunotherapy for acute lymphoblastic leukaemia. Lancet (1969) 13.03
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Language bias in randomised controlled trials published in English and German. Lancet (1997) 7.29
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum (1998) 6.16
Gene Ontology annotations and resources. Nucleic Acids Res (2012) 6.13
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Spurious precision? Meta-analysis of observational studies. BMJ (1998) 5.45
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect (1996) 4.26
Cancer in the elderly: why so badly treated? Lancet (1990) 3.67
Complete DNA sequence of yeast chromosome XI. Nature (1994) 3.51
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut (2009) 3.24
Lactase haplotype diversity in the Old World. Am J Hum Genet (2000) 3.19
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum (1995) 3.10
Musculoskeletal pain in Europe: its impact and a comparison of population and medical perceptions of treatment in eight European countries. Ann Rheum Dis (2004) 2.95
Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol (1994) 2.94
Peroxisomal protein import is conserved between yeast, plants, insects and mammals. EMBO J (1990) 2.93
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue. J Clin Invest (2001) 2.77
Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol (2001) 2.77
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis (2006) 2.72
[Rheumatology: Integration into student training--the RISA- Study. Results of a survey exploring the scale of education and training in rheumatology at German universities]. Z Rheumatol (2004) 2.69
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis (2011) 2.67
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet (2000) 2.63
Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis (2009) 2.61
Evaluation of a novel 7-joint ultrasound score in daily rheumatologic practice: a pilot project. Arthritis Rheum (2009) 2.57
Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J (2001) 2.52
Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am (1998) 2.52
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of Xenopus oocytes and the induction of macrophage chemoattraction. Cell Tissue Res (2001) 2.45
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol (2000) 2.45
Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci U S A (1994) 2.45
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
[Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire]. Z Rheumatol (1997) 2.34
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect (2011) 2.23
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood (2000) 2.21
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
Chlamydia and Borrelia DNA in synovial fluid of patients with early undifferentiated oligoarthritis: results of a prospective study. Arthritis Rheum (2001) 2.20
Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum (1994) 2.19
Anaerobic nitrate reductase (narGHJI) activity of Mycobacterium bovis BCG in vitro and its contribution to virulence in immunodeficient mice. Mol Microbiol (2000) 2.18
Tumor seeding following laparoscopy: international survey. World J Surg (1999) 2.18
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis (2005) 2.15
The International Classification of Functioning, Disability and Health: a new tool for understanding disability and health. Disabil Rehabil (2003) 2.14
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum (2011) 2.14
Q fever endocarditis in the United States. Ann Intern Med (1979) 2.12
Huntington's disease: genetic heterogeneity in black African patients. S Afr Med J (2008) 2.12
Drosophila Stardust is a partner of Crumbs in the control of epithelial cell polarity. Nature (2001) 2.12
High levels of circulating early apoptic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus (1998) 2.07
Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol (1993) 2.07
Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation (1996) 2.05
[Benign symmetric lipomatosis--Launois-Besaude syndrome. A case report]. Tidsskr Nor Laegeforen (1996) 2.05
Complete DNA sequence of yeast chromosome II. EMBO J (1994) 1.97
Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol (1988) 1.96
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis (2006) 1.94
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia (2009) 1.93
Use of repetitive sequences and the polymerase chain reaction technique to classify genetically related Bradyrhizobium japonicum serocluster 123 strains. Appl Environ Microbiol (1993) 1.92